Cardioprotective Effects of Pioglitazone in Type 2 Diabetes

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pio-glitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium–glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be miti-gated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.

Original languageEnglish (US)
Pages (from-to)243-247
Number of pages5
JournalDiabetes Spectrum
Volume34
Issue number3
DOIs
StatePublished - Aug 2021

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Cardioprotective Effects of Pioglitazone in Type 2 Diabetes'. Together they form a unique fingerprint.

Cite this